Quick Answer
Greenwich LifeSciences, Inc. reported R&D Expense of $12.95 million for fiscal year 2024.
Greenwich LifeSciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $12.95M | +68.2% |
| 2023 | $7.70M | +18.9% |
| 2022 | $6.48M | +81.9% |
| 2021 | $3.56M | +236.6% |
| 2020 | $1.06M | -59.4% |
| 2019 | $2.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.52M | +53.6% | +0.4% |
| June 30, 2025 | $3.51M | +52.0% | +34.9% |
| March 31, 2025 | $2.60M | +18.5% | +13.5% |
| September 30, 2024 | $2.29M | +6.2% | -0.7% |
| June 30, 2024 | $2.31M | +67.3% | +5.2% |
| March 31, 2024 | $2.19M | +20.1% | +1.7% |
| September 30, 2023 | $2.16M | +25.2% | +56.4% |
| June 30, 2023 | $1.38M | +117.9% | -24.5% |
- Greenwich LifeSciences, Inc. showed an increase of +68.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2024 period, Greenwich LifeSciences, Inc.’s r&d expense has grown by 396.9% (from $2.61 million to $12.95 million).
- The most recent figure is from Greenwich LifeSciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: